Can I read Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial on EtoBox?

Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial by Akira Ooki; Satoshi Morita; Akihito Tsuji; Shigeyoshi Iwamoto; Hiroki Hara; Hiroaki Tanioka; Hironaga Satake; Masato Kataoka; Masahito Kotaka; Yoshinori Kagawa; Masato Nakamura; Tatsushi Shingai; Masashi Ishikawa; Yasuhiro Miyake; Takeshi Suto; Yojiro Hashiguchi; Taichi Yabuno; Masahiko Ando; Junichi Sakamoto; Kensei Yamaguchi is a Medicine article available to read on EtoBox.

What is Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial about?

## Purpose Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus chemotherapy. ## Methods The data were collected from a prospective trial that assessed HRQOL using the EORTC QLQ-C30. The impact of ETS on HRQOL was estimated using a linear mixed-effects model for repeated measures. ## Results ETS was achieved in 82 (64.1%) of 128 mCRC patients treated with first-line cetuximab plus chemotherapy, and these patients had a significantly longer OS than those without ETS (HR, 0.38; 95% CI, 0.20–0.72; P = .002). Asymptomatic patients with ETS had a favorable OS, while symptomatic patients without ETS had a worse OS (2-year OS rates, 77.8% vs. 42.5%). Symptomatic patients with ETS had similar outcomes as asymptomatic patients without ETS (2-year OS rates, 64.1% vs. 67.0%). For symptomatic patients, ETS was associated with improved HRQOL scores between baseline and 8 weeks: the mean changes for patients with and without ETS were 5.86 and -4.94 for global health status (GHS)/QOL, 2

Who reads Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial?

Author

Akira Ooki; Satoshi Morita; Akihito Tsuji; Shigeyoshi Iwamoto; Hiroki Hara; Hiroaki Tanioka; Hironaga Satake; Masato Kataoka; Masahito Kotaka; Yoshinori Kagawa; Masato Nakamura; Tatsushi Shingai; Masashi Ishikawa; Yasuhiro Miyake; Takeshi Suto; Yojiro Hashiguchi; Taichi Yabuno; Masahiko Ando; Junichi Sakamoto; Kensei Yamaguchi

Published

2022

Language

EN

Field

Medicine (Health Sciences)